N/A N=29 Efficacy of Cantharidin in Molluscum Contagiosum
Molluscum Contagiosum, Skin Disease
Primary: Patients Experiencing Complete Clearance of All Molluscum Lesions. — 1; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=266 Cantharidin Application in Molluscum Patients-1
Molluscum Contagiosum
Primary: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) — 74; 19 Participants — p=<0.0001
Phase 2 N=256 A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
Molluscum Contagiosum
Primary: Proportion of Subjects Achieving Complete Clearance at Week 12 — 5; 16; 13; 18 Participants
Phase 3 N=262 Cantharidin Application in Molluscum Patients
Molluscum Contagiosum
Primary: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) — 81; 15 Participants
Phase 3 N=891 A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
Molluscum Contagiosum
Primary: Complete Clearance of All Treatable MC at Week 12 — 144; 88 Participants
Phase 2 N=94 Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
Molluscum Contagiosum
Primary: Number of Subjects Who Achieve Complete Clearance at 6 Weeks — 10; 7; 2; 3 Participants
Phase 2 N=30 Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
Molluscum Contagiosum
Primary: Number of Participants With Total Lesion Clearance — 11 Participants
Phase 2 N=33 Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
Molluscum Contagiosum
Primary: The Presence or Absence of Systemic Exposure to Cantharidin by the Collection and Analysis of Plasma Samples From Patients With 21 or More Molluscum Lesions Following…
Phase 4 N=17 Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
Verruca Vulgaris · Molluscum Contagiosum Skin Infection
Primary: Numbers of Lesions With no Response — 8; 9 lesions — p=0.534
Phase 2 N=56 Cantharidin and Occlusion in Verruca Epithelium
Common Wart · Warts Hand · Warts
Primary: Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) — 4 Participants
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
N/A N=124 CellFX System for the Treatment of Cutaneous Non-Genital Warts
Warts · Warts Hand · Verruca
Primary: Percentage of Verrucae Cleared — 67.6 percentage of verrucae clearance
N/A N=66 A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Verruca Viral
Primary: Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts — 25; 22; 2; 6 Participants
Phase 3 N=36 Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients
Varicella
Primary: Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample — 6.49; 6.46; 6.07; 6.02 VZV genome copies per sample
Phase 2 N=21 Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis
Psoriasis
Primary: Mean Change From Baseline to Day 28 in PSS (Psoriasis Severity Score) of the Treatment Target Lesions Compared to Placebo Target Lesions — -1.9; -1.5 PSS score
N/A N=24 Nanopulse Efficacy Study for the Treatment of Common Warts
Common Warts
Primary: Clinical Clearance of Warts — 13; 4; 2 # of warts
Phase 2 N=28 Mechlorethamine Induced Contact Dermatitis Avoidance Study
Cutaneous T-cell Lymphoma · Cutaneous T-cell Lymphoma Stage I · Mycosis Fungoides
Primary: Incidence of Moderate to Severe Contact Dermatitis by SCORD Scoring — 16; 11 patients
N/A N=150 CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts
Warts · Warts Hand · Verruca
Primary: Percentage of Warts Resolved — 80.7; 73.1 percentage of warts resolved
Phase 4 N=146 Preventing Staphylococcal (Staph) Infection
Staphylococcal Infections
Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356
N/A N=50 Spread of Dermatophytes Among Families
Onychomycosis · Tinea Pedis
Primary: Dermatophyte Species Distribution — 50; 37; 5; 12 isolates
Phase 4 N=10 A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008
Phase 3 N=355 A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
Molluscum Contagiosum
Primary: Complete Clearance of All Treatable MC at Week 12 — 71; 24 Participants
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 2 N=20 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Acne Vulgaris
Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants